Michael Cook
@Michael_R_Cook4
Assistant professor Hematology/Oncology @PennMedicine, focus in Lymphoma. Penn State '13, Temple Med '17. Fluent in Pittsburghese.
Вам может понравиться
Prolonged MTR for induction and consolidation is a safe alternative treatment strategy for the management of PCNSL. ow.ly/tkO350WJ6fw #lymphoidneoplasia #lymphoma
Just out at @JCO_ASCO: COALITION study comparing glofitamab + PolaR-CHP vs glofit-R-CHOP in frontline large B cell lymphoma - very exciting n=80 ORR 100% CRR 98% 21 month PFS 86%, OS 92% ascopubs.org/doi/10.1200/JC… Congrats @mike_dickinson1 @AdrianMinson ! #lymsm #18ICML
CD19-specific CAR T cells engineered to secrete interleukin-18 were used to treat patients with lymphoma after previous CAR T failure, with a complete or partial response of 81% and a complete response of 52%. Full trial results: nej.md/4jSiXkX
Comparison of CAR T-cell vs. bispecific Ab as 3rd(+) line DLBCL Rx: A Meta-analysis 16 studies: 1,347 pts in pooled analysis •CAR-T: superior efficacy: ⬆️CR & pooled 1yr PFS cf bispecifics but •CAR-T exhibits ⬆️ incidence ≥G3 AEs cf bispecifics ashpublications.org/blood/article/…
And the total for THON 2024, Treasure Every Adventure, is $16,955,683.63
If there’s not a graphic, depicting the three Steelers QBs as the ghosts of Christmas past, present and future, I’m going to be v disappointed.
Exciting news! We've established a groundbreaking collaboration with the University of Pennsylvania's (UPenn) School of Clinical Medicine as part of our Centres of Excellence (CoE) programme. We can't wait to see how this collaboration will take us closer to a cure for FL!
WATCH: Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axi-cel in patients with R/R LBCL. @Michael_R_Cook4 @PennMedicine @ASH_hematology #ASH23 #lymsm onclive.com/view/dr-cook-o…
#ASH23 continues to amaze with surprise meetups on hallways and sidewalks!! So nice to see you both @ErikaHaydu @MassGeneralNews and @Michael_R_Cook4 @PennMedicine Good old @ASCO @AACR #Vail2021 company!! @VUMCHemOnc
Thanks to @michael_r_cook4, of @PennMedicine, for joining us during @ASH_hematology to speak about the impact of bridging therapy prior to axi-cel in R/R LBCL! Head to our site to see how day 1 of the meeting wraps! #ASH23 #lymsm onclive.com/conference/ash
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL @michael_r_cook4 @PennMedicine @ASH_Hematology #ASH23 #lymsm onclive.com/view/addition-…
#ASH23 @Michael_R_Cook4 from @PennMedicine discusses impact of bridging therapy (BT) prior to axi-cel treatment in pts with LBCL. N=1307; ORR with and without bridging therapy=70% vs 79%; CR= 51% vs 64% respectively. Grade ≥3 CRS and ICANS in BT vs no BT=12% and 30% vs 10% and…
Ouch. Bendamustine is bad news for CAR T-cells in FL too - figure below from just-published ZUMA-5 data in @BloodJournal as per @gloria_iacoboni I wonder whether this effect is overcome with BsAbs given repeat stimulation of the T-cells ashpublications.org/blood/article/… @AshAlizadeh
Check out the data published today on ZUMA-5 trial in Blood, figure 3 😉
ASH is strongly urging @ABIMcert to take immediate action to establish a new MOC program that does not involve high-stakes assessments to better serve our members. Read the full text of ASH’s letter: loom.ly/xXS6uqQ @ABMSCert
RR #DLBCL #Lymphoma & secondary #CNS Involvement #CART #celltherapy has seen more #realworld data of late. Latest is the🇩🇪 #registry LONG-TERM #data from @NicoGagelmann & team 👍reassuring - outcomes comparable with those without, & no ⬆️in #ICANS or #CRS. ashpublications.org/bloodadvances/…
Ladies and gentlemen, I present you with the worst take you’ll see all year.
Theory from @ProFootballTalk on @937theFan. Thinks the Steelers might not be making George Pickens the focal point of the offense because they don't want to create a "contractual monster". They don't want to pay him #1 WR money. 30+ million a year. Hmmm.
Final Version published in @BloodJournal, check it out! ashpublications.org/blood/article-…
United States Тренды
- 1. Epstein 1.11M posts
- 2. Tarik Skubal 2,391 posts
- 3. Steam Machine 59.7K posts
- 4. Virginia Giuffre 63K posts
- 5. Starship 13.2K posts
- 6. #LightningStrikes N/A
- 7. Bill Clinton 27.4K posts
- 8. Valve 40.5K posts
- 9. Xbox 65.2K posts
- 10. Dana Williamson 11.4K posts
- 11. Boebert 52.7K posts
- 12. Situation Room 9,730 posts
- 13. Beal 7,491 posts
- 14. #dispatch 59K posts
- 15. Tim Burchett 21.1K posts
- 16. Maxwell 141K posts
- 17. AL Cy Young N/A
- 18. Jake Paul 4,386 posts
- 19. H-1B 120K posts
- 20. Hagel N/A
Вам может понравиться
-
Ayushi Chauhan
@Chauhan_AF -
Jennifer A. Marks, MD
@jennifermarksmd -
Samantha Armstrong
@SamArmstrongMD -
Kai Rejeski
@KRejeski -
Michael Serzan, MD
@MikeSerzanMD -
Samuel Kareff, MD, MPH
@SamuelKareffMD -
Reetu Mukherji, MD
@ReetuMukherjiMD -
Sunnie Kim, MD
@SunnieSKim -
Richa Parikh
@richaparikh36 -
Owhofasa Agbedia, MD, MPH, FACP
@FasaAgbedia -
Shivani Dalal MD
@ShivaniDalalMD -
Bhavisha Patel
@bhavishap29
Something went wrong.
Something went wrong.